NCT03777176 - A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

August 31, 2020

Study Completion Date

October 5, 2020

Conditions

Congenital Hyperinsulinism

Interventions

DRUG

Dasiglucagon

Glucagon analog

OTHER

Standard of Care

Standard of care according to site and/or country

Trial Locations (10)

Children's Hospital of Colorado, Aurora

Children's Hospital of Philadelphia, Philadelphia

Otto von Guericke University Magdeburg, Department of Pediatrics, Magdeburg

University Hospital Düsseldorf, Department of Pediatrics, Düsseldorf

Cook Children's Medical Center, Fort Worth

Hadassah Medical Center, Jerusalem

NHS Greater Glasgow and Clyde, Glasgow

Alder Hey Children'sHospital NHS Foundation Trust, Liverpool

Great Osmond Street Hospital for Children NHS Foundation Trust, London

Central Manchester University Hospital NHS Foundation Trust, Manchester